美国生物科技公司Revance Therapeutics Inc(RVNC)今日盘中股价大跌26.82%,收于3.56美元,引发市场广泛关注。这一重挫主要由于公司两大重要消息令投资者对其未来增长前景的担忧加剧。
首先,Revance宣布撤回之前提供的全年业绩指引,不再给出任何前瞻性预测。作为一家尚未实现盈利的生物科技公司,管理层的业绩预测往往被视为衡量其发展潜力的重要参考依据。此次指引撤回无疑加剧了投资者对公司能否实现长期增长的质疑。
另一方面,Revance与Crown Labs的合并交易也出现延迟,双方同意将要约收购的最后期限延长至11月12日。该笔并购交易拖延较久,更令投资者对其能否最终完成产生重大疑虑,进一步打击了市场对Revance前景的信心。值得注意的是,Revance股价在过去一段时间内已累积下跌超过32%,持续的下滑走势更为今日重挫火上浇油。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.